Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT01492907
Study Design:
This is a single institution pilot study to recruit 4 patients with operable pancreatic cancer scheduled for a pancreatectomy and 4 age/sex matched normal controls. Both groups will receive a single oral dose of radiolabeled MelQx followed by serial blood draws over an 8 hour period and urine collections over a 24 hour period. In addition, normal pancreatic tissue and normal small bowel tissue will be collected by Tissue Procurement from resected (waste) tissue at the time of pancreatectomy on the 4 pancreatic cancer patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Minneapolis, Minnesota, 55455, United States
This is not a therapeutic trial. It is an etiologic investigation of meat-borne carcinogens and possible role in pancreatic cancer.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Cancer cases are eligible for participation if all of the following criteria are met:
Healthy controls are eligible for participation if all of the following criteria are met:
Exclusion criteria
Cancer cases are not eligible for participation if any of the following criteria are met:
For the purposes of this study to reduce the risk of recruiting a potentially unresectable patient:
Healthy controls are not eligible for participation if any of the following criteria are met:
On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
Other names: [14C]-MeIQx (2 Amino-3,8-dimethylimidazo[4,5 f]quinoxaline-2-[14C])
Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
Time frame: Pre MeIQx Administration, 1/2, 1, 2, 4, 6, 8 Hours Post MeIQx Administration
Metabolite levels will be expressed as the percent of total recovered radioactivity in plasma. Metabolite profiles will be qualitatively compared between cases and controls, which will include the mean, median, standard deviation, range and 90% confidence interval for the major detoxification metabolites.
Time frame: 0-4, 4-8 and 8-24 Hours Post MeIQx Administration
Metabolite levels will be expressed as the percent of total recovered radioactivity in urine. Metabolite profiles will be qualitatively compared between cases and controls, which will include the mean, median, standard deviation, range and 90% confidence interval for the major detoxification metabolites.
Time frame: 4-8 Hours Post MeIQx Administration
In the pancreatic cancer patients, uninvolved/normal resected (waste) tissue from the surgery will be sent to Lawrence Livermore National Laboratory (LLNL) for DNA extraction following previously published methods. New [14C]MeIQx-DNA adducts formed at physiological concentrations will be detected and quantified in resected tissue with highly sensitive accelerator mass spectrometry (AMS).
Time frame: 4-8 Hours Post Administration
DNA adducts already present in resected tissue will be quantified and characterized with a newly improved technique, electrospray capillary high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS).
University of Minnesota
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05675059
Digestive System Diseases, Digestive System Neoplasms
Tampa, Florida, United States
View Trial DetailsNCT03410030
Digestive System Diseases, Digestive System Neoplasms
Scottsdale, Arizona, United States
View Trial DetailsNCT04553926
Adnexal Diseases, Breast Cancer
Ansan, South Korea
View Trial DetailsNCT03096054
Breast Cancer (Triple Negative Type), Breast Diseases
Belfast, United Kingdom
View Trial Details